The presence of CTD, sex, ECOG performance status, and tumor-node-metastasis clinical stage were the independent prognostic factors in all patients with non–small cell LC (NSCLC). 35 months HR, 26.009 p < 0.001) of first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment between patients with AC with and without CTDs.
A significant difference was observed in mPFS and mOS (6 months vs. The median progression-free survival (mPFS) and overall survival (mOS) of first-line chemotherapy did not differ between patients with lung adenocarcinoma (AC) with and without CTDs. The Eastern Cooperative Oncology Group (ECOG) performance score for LC-CTD patients was worse than that for matched non-CTD LC patients. Results: The median duration from the diagnosis of CTDs to LC was 17 years. Medical records, therapeutic efficacy of cancer, and outcomes were analyzed. Methods: This retrospective cohort study investigated 29 patients with LC with CTDs, and 116 patients with LC without CTDs were enrolled as case-matched control cohorts. Evidence supports that poor survival may be associated with the presence of CTDs in patients with LC. 2Department of Radiation Oncology, China-Japan Friendship Hospital, Beijing, Chinaīackground: Studies have demonstrated a close association between connective tissue diseases (CTDs) and lung cancer (LC).1Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.Ningning Li 1†, Liwei Gao 2†, Chunmei Bai 1*, Lin Zhao 1 and Yajuan Shao 1
0 kommentar(er)
